Pharmaceutical firm plans $10.4M in new equipment, 60 jobs
The company has requested a tax break from Indianapolis officials on the project that would save it about $484,000 over eight years.
The company has requested a tax break from Indianapolis officials on the project that would save it about $484,000 over eight years.
Eli Lilly and Co. employees knew the Alzheimer's treatment solanezumab was not a sure bet. But that didn’t make the pain any less acute after the company announced the drug had failed to demonstrate effectiveness during a 2,100-patient Phase 3 clinical trial.
For more than two years, Eli Lilly and Co. has pushed the message that the worst days are over and a brighter future is just around the corner. Now, finally, Wall Street is starting to believe.
Indianapolis-based Elevate Ventures said it made the investment through the 21st Century Research & Technology Fund, which is reserved for Indiana companies.
Named AZD3293, the drug belongs to a novel class of drugs that block production of amyloid, a protein that causes plaque to build up in the brain of Alzheimer’s patients.
Within six months, Eli Lilly and Co. could know whether the Food and Drug Administration has approved its latest drug, baricitinib, a once-a-day tablet for treating rheumatoid arthritis.
Unprecedented results from a cardiovascular study on a diabetes medicine sold by Eli Lilly and Co. turns up the pressure on rival Novo Nordisk, which will release data from a similar study on its competing drug next year.
The experimental medicine, called romosozumab, showed better results than Eli Lilly and Co.’s Forteo after 12 months, Amgen and UCB said in a joint statement Wednesday.
Shares of Eli Lilly and Co. stagnated in Wednesday morning trading as investors and patients wished that the effects of solanezumab were more pronounced. Rival Biogen offered muddy results from its own Alzheimer’s drug.
After years of pipeline failures, Eli Lilly and Co. is on a bit of a hot streak. This month alone, the Indianapolis-based drugmaker has reported positive results from clinical trials of four experimental drugs.
The results of an experimental drug for Alzheimer’s disease provide the best evidence so far that the memory-robbing condition is caused by an errant protein in the brain. Drugmakers including Eli Lilly have been concentrating their Alzheimer’s research on that area.
Although the experimental diabetes drug is in final-stage testing and showing promising results, Lilly wants to better understand its effect on liver fat.
If approved, Baricitinib may bring Lilly $673 million in 2020, according to the average of five analysts’ estimates compiled by Bloomberg.
Lilly is finally putting meat on the bones of its predictions about its experimental diabetes and cancer drugs. That gives investors the certainty they crave that Lilly’s future revenue won’t remain in its 2014 doldrums.
The Indianapolis-based drugmaker said Thursday that peglispro produced statistically significant lower blood sugar levels in patients when compared to people who took the Sanofi insulin Lantus in two late-stage studies of people with type 1 diabetes.
Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.
Founders of Chondrial Therapeutics believe that if further testing validates their treatment for Friedreich’s ataxia, it could be a blockbuster with annual sales topping $1 billion.
Results of a Roche clinical trial mirror those produced by an experimental Lilly drug two years ago. Lilly executives say that validates their approach in the multi-billion-dollar race to market the first drug to reverse Alzheimer’s.
With federal health research funding in decline, Indianapolis-based Regenstrief Institute Inc. wants to make up the difference by serving pharmaceutical companies, medical device makers, health insurers and hospital systems.
Shares of Endocyte Inc. skidded 15 percent Wednesday after industry giant Merck & Co. Inc. decided it would give up on developing Endocyte cancer drug vintafolide.